Radiopharmaceutical tracers for cardiac imaging

Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiova...

Descripción completa

Detalles Bibliográficos
Autores principales: Manabe, Osamu, Kikuchi, Tatsuya, Scholte, Arthur J. H. A., El Mahdiui, Mohammed, Nishii, Ryuichi, Zhang, Ming-Rong, Suzuki, Eriko, Yoshinaga, Keiichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133155/
https://www.ncbi.nlm.nih.gov/pubmed/29196910
http://dx.doi.org/10.1007/s12350-017-1131-5
Descripción
Sumario:Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiovascular events. Several radiopharmaceutical tracers have recently been developed to evaluate CVD by targeting myocardial perfusion, metabolism, innervation, and inflammation. This article reviews old and newer used in nuclear cardiac imaging. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12350-017-1131-5) contains supplementary material, which is available to authorized users.

Ejemplares similares